Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $18.21 million. The enterprise value is $3.24 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.55 million shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | 5.55M |
| Shares Outstanding | 5.55M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 2.84% |
| Owned by Institutions (%) | 9.59% |
| Float | 5.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.07 |
| Forward PS | 33.00 |
| PB Ratio | 1.26 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.25, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.25 |
| Quick Ratio | 7.90 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.92% and return on invested capital (ROIC) is -23.50%.
| Return on Equity (ROE) | -32.92% |
| Return on Assets (ROA) | -21.45% |
| Return on Invested Capital (ROIC) | -23.50% |
| Return on Capital Employed (ROCE) | -44.62% |
| Revenue Per Employee | $270,168 |
| Profits Per Employee | -$342,202 |
| Employee Count | 16 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.53% in the last 52 weeks. The beta is 1.06, so Lipocine's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -34.53% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 3.14 |
| Relative Strength Index (RSI) | 62.49 |
| Average Volume (20 Days) | 55,370 |
Short Selling Information
The latest short interest is 106,280, so 1.91% of the outstanding shares have been sold short.
| Short Interest | 106,280 |
| Short Previous Month | 108,957 |
| Short % of Shares Out | 1.91% |
| Short % of Float | 1.97% |
| Short Ratio (days to cover) | 1.89 |
Income Statement
In the last 12 months, Lipocine had revenue of $4.32 million and -$5.48 million in losses. Loss per share was -$1.02.
| Revenue | 4.32M |
| Gross Profit | 4.32M |
| Operating Income | -6.31M |
| Pretax Income | -5.48M |
| Net Income | -5.48M |
| EBITDA | -6.25M |
| EBIT | -6.31M |
| Loss Per Share | -$1.02 |
Full Income StatementBalance Sheet
The company has $15.13 million in cash and $157,200 in debt, giving a net cash position of $14.97 million or $2.70 per share.
| Cash & Cash Equivalents | 15.13M |
| Total Debt | 157,200 |
| Net Cash | 14.97M |
| Net Cash Per Share | $2.70 |
| Equity (Book Value) | 14.14M |
| Book Value Per Share | 2.61 |
| Working Capital | 14.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.14 million and capital expenditures -$10,019, giving a free cash flow of -$5.15 million.
| Operating Cash Flow | -5.14M |
| Capital Expenditures | -10,019 |
| Free Cash Flow | -5.15M |
| FCF Per Share | -$0.93 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -145.98% and -126.66%.
| Gross Margin | 100.00% |
| Operating Margin | -145.98% |
| Pretax Margin | -126.66% |
| Profit Margin | -126.66% |
| EBITDA Margin | -144.56% |
| EBIT Margin | -145.98% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.65% |
| Shareholder Yield | -0.65% |
| Earnings Yield | -30.07% |
| FCF Yield | -28.28% |
Analyst Forecast
The average price target for Lipocine is $7.00, which is 113.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 113.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 36.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -11.67 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.67 |
| Piotroski F-Score | 1 |
